Institution
Institute of Chartered Accountants of Nigeria
About: Institute of Chartered Accountants of Nigeria is a based out in . It is known for research contribution in the topics: Population & Adipose tissue. The organization has 528 authors who have published 579 publications receiving 18688 citations.
Topics: Population, Adipose tissue, Insulin resistance, Genome-wide association study, Extracorporeal membrane oxygenation
Papers published on a yearly basis
Papers
More filters
Karolinska Institutet1, University of Texas Health Science Center at Houston2, National Institutes of Health3, University of Edinburgh4, University of Rochester5, University of Minnesota6, United States Environmental Protection Agency7, Johns Hopkins University8, Leiden University9, Heidelberg University10, University of California, Los Angeles11, University of Washington12, University of Paris13, Institute of Chartered Accountants of Nigeria14, University of Michigan15, University of Split16, Fred Hutchinson Cancer Research Center17, Baylor College of Medicine18, University of Glasgow19, University of Sydney20, Erasmus University Rotterdam21, University of Jena22, French Institute of Health and Medical Research23, Harvard University24, University of Vermont25, University of Bern26, Kaiser Permanente27, Population Health Research Institute28, Lund University29, University of Iceland30, Synlab Group31, Autonomous University of Barcelona32, Medical University of Graz33, Imperial College London34, St George's, University of London35, VA Boston Healthcare System36, United States Department of Veterans Affairs37
TL;DR: The meta-analysis identified 13 novel genetic loci regulating FVIII and VWF plasma levels, 10 of which were validated functionally and provided some evidence for a causal role of these proteins in thrombotic events.
Abstract: Background: Factor VIII (FVIII) and its carrier protein von Willebrand factor (VWF) are associated with risk of arterial and venous thrombosis and with hemorrhagic disorders. We aimed to identify a...
87 citations
Hospital for Special Surgery1, Boston University2, McMaster University3, Medical College of Wisconsin4, University of Paris5, Cairo University6, University of Adelaide7, Yale University8, Saint Louis University9, Washington University in St. Louis10, I-Shou University11, University of California, San Diego12, Veterans Health Administration13, University of Alabama at Birmingham14, University of Washington15, Scientific University of the South16, University of Texas Southwestern Medical Center17, Institute of Chartered Accountants of Nigeria18, Malaghan Institute of Medical Research19, University College London20, University of Queensland21, HealthPartners22, Harvard University23, University of California, San Francisco24, National Institutes of Health25, Boston Children's Hospital26, Beth Israel Deaconess Medical Center27, Stanford University28, Brigham and Women's Hospital29
TL;DR: In this paper, the early experiences of adults with systemic rheumatic disease who received the COVID-19 vaccine were described, and the most reported adverse events were fatigue/somnolence (33.4%), headache (27.7%), muscle/joint pains (22.8%), and fever/chills (19.9%).
Abstract: Background We describe the early experiences of adults with systemic rheumatic disease who received the COVID-19 vaccine. Methods From 2 April to 30 April 2021, we conducted an online, international survey of adults with systemic rheumatic disease who received COVID-19 vaccination. We collected patient-reported data on clinician communication, beliefs and intent about discontinuing disease-modifying antirheumatic drugs (DMARDs) around the time of vaccination, and patient-reported adverse events after vaccination. Results We analysed 2860 adults with systemic rheumatic diseases who received COVID-19 vaccination (mean age 55.3 years, 86.7% female, 86.3% white). Types of COVID-19 vaccines were Pfizer-BioNTech (53.2%), Oxford/AstraZeneca (22.6%), Moderna (21.3%), Janssen/Johnson & Johnson (1.7%) and others (1.2%). The most common rheumatic disease was rheumatoid arthritis (42.3%), and 81.2% of respondents were on a DMARD. The majority (81.9%) reported communicating with clinicians about vaccination. Most (66.9%) were willing to temporarily discontinue DMARDs to improve vaccine efficacy, although many (44.3%) were concerned about rheumatic disease flares. After vaccination, the most reported patient-reported adverse events were fatigue/somnolence (33.4%), headache (27.7%), muscle/joint pains (22.8%) and fever/chills (19.9%). Rheumatic disease flares that required medication changes occurred in 4.6%. Conclusion Among adults with systemic rheumatic disease who received COVID-19 vaccination, patient-reported adverse events were typical of those reported in the general population. Most patients were willing to temporarily discontinue DMARDs to improve vaccine efficacy. The relatively low frequency of rheumatic disease flare requiring medications was reassuring.
86 citations
TL;DR: The Ad-DiaRem is proposed, which includes two additional clinical variables, as an optimised tool with improved accuracy to predict diabetes remission 1 year post-RYGB, and might be helpful for personalised management of individuals with diabetes when considering bariatric surgery in routine care.
Abstract: Not all people with type 2 diabetes who undergo bariatric surgery achieve diabetes remission. Thus it is critical to develop methods for predicting outcomes that are applicable for clinical practice. The DiaRem score is relevant for predicting diabetes remission post-Roux-en-Y gastric bypass (RYGB), but it is not accurate for all individuals across the entire spectrum of scores. We aimed to develop an improved scoring system for predicting diabetes remission following RYGB (the Advanced-DiaRem [Ad-DiaRem]). We used a retrospective French cohort (n = 1866) that included 352 individuals with type 2 diabetes followed for 1 year post-RYGB. We developed the Ad-DiaRem in a test cohort (n = 213) and examined its accuracy in independent cohorts from France (n = 134) and Israel (n = 99). Adding two clinical variables (diabetes duration and number of glucose-lowering agents) to the original DiaRem and modifying the penalties for each category led to improved predictive performance for Ad-DiaRem. Ad-DiaRem displayed improved area under the receiver operating characteristic curve and predictive accuracy compared with DiaRem (0.911 vs 0.856 and 0.841 vs 0.789, respectively; p = 0.03); thus correcting classification for 8% of those initially misclassified with DiaRem. With Ad-DiaRem, there were also fewer misclassifications of individuals with mid-range scores. This improved predictive performance was confirmed in independent cohorts. We propose the Ad-DiaRem, which includes two additional clinical variables, as an optimised tool with improved accuracy to predict diabetes remission 1 year post-RYGB. This tool might be helpful for personalised management of individuals with diabetes when considering bariatric surgery in routine care, ultimately contributing to precision medicine.
85 citations
TL;DR: It is shown here that mouse embryonic limb MCT cells expressing the transcription factor Osr1, differentiate into fibrogenic and adipogenic cells in vivo and in vitro defining an embryonic FAP-like population, and genetic lineage tracing shows that developmental OsR1+ cells give rise to a subset of adult FAPs.
Abstract: Fibro-adipogenic progenitors (FAPs) are an interstitial cell population in adult skeletal muscle that support muscle regeneration. During development, interstitial muscle connective tissue (MCT) cells support proper muscle patterning, however the underlying molecular mechanisms are not well understood and it remains unclear whether adult FAPs and embryonic MCT cells share a common lineage. We show here that mouse embryonic limb MCT cells expressing the transcription factor Osr1, differentiate into fibrogenic and adipogenic cells in vivo and in vitro defining an embryonic FAP-like population. Genetic lineage tracing shows that developmental Osr1+ cells give rise to a subset of adult FAPs. Loss of Osr1 function leads to a reduction of myogenic progenitor proliferation and survival resulting in limb muscle patterning defects. Transcriptome and functional analyses reveal that Osr1+ cells provide a critical pro-myogenic niche via the production of MCT specific extracellular matrix components and secreted signaling factors. Fibro-adipogenic progenitors (FAPs) form part of interstitial muscle connective tissue (MCT) in adults but the origin of this non-myogenic lineage is unclear. Here, the authors show that Odd skipped related 1 (Osr1) in mice marks embryonic MCT, giving rise to FAPs, and loss of Osr1 in the limb causes muscle defects.
85 citations
Imperial College London1, Nanyang Technological University2, St George's, University of London3, University of Western Australia4, University of Amsterdam5, University of the Witwatersrand6, University of Manchester7, Masaryk University8, Saint Joseph's University9, Sultan Qaboos University10, Medical University of Łódź11, University of Oslo12, Instituto Nacional de Saúde Dr. Ricardo Jorge13, Institute of Chartered Accountants of Nigeria14, Charles University in Prague15, Innsbruck Medical University16, University of Ljubljana17, University of Lisbon18, McGill University19, Peking Union Medical College20, Ege University21, National University of Singapore22, University of Latvia23, Saarland University24, University of Ioannina25, Capital Medical University26, Tallaght Hospital27, University of Cape Town28, Heidelberg University29, Kyrgyz State Medical Academy30, University of Basel31, Universiti Teknologi MARA32, Linköping University33, University of Copenhagen34, University of Debrecen35, Vilnius University36, University of Zagreb37, Mashhad University of Medical Sciences38, University of the Philippines39, Technische Universität München40, United Arab Emirates University41, University of Monastir42, National Taiwan University43, University of Malta44, The Chinese University of Hong Kong45, Slovak Medical University46, University of Helsinki47, Osaka University48, University of Milan49
TL;DR: The European Atherosclerosis Society FH Studies Collaboration (EAS FHSC) is a new initiative of international stakeholders which will help establish a global FH registry to generate large-scale, robust data on the burden of FH worldwide.
85 citations
Authors
Showing all 528 results
| Name | H-index | Papers | Citations |
|---|---|---|---|
| Ronald M. Evans | 199 | 708 | 166722 |
| Thierry Poynard | 119 | 668 | 64548 |
| Heikki Joensuu | 108 | 571 | 50300 |
| Gilles Montalescot | 100 | 641 | 58644 |
| François Cambien | 92 | 251 | 36260 |
| Antoine Danchin | 80 | 483 | 30219 |
| Laurence Tiret | 79 | 194 | 25231 |
| Karine Clément | 78 | 275 | 32185 |
| Karine Clément | 73 | 228 | 14710 |
| Pascal Ferré | 69 | 241 | 23969 |
| Michael T. Osterholm | 68 | 260 | 22624 |
| Vincent Jarlier | 67 | 278 | 17060 |
| Florent Soubrier | 67 | 226 | 24486 |
| Stephen H. Caldwell | 66 | 308 | 18527 |
| Christian Funck-Brentano | 64 | 267 | 70432 |